Participating Companies

Affimed N.V. [AFMD] $708 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) en­rolling in a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. [more in­for­ma­tion]
Amarin Corporation [AMRN] $2,040 MM MCap
Com­mer­cial­iz­ing Vas­ce­pa, the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA. First 9mo rev’s of 2020 ~$450M. [more in­for­ma­tion]
Apexigen
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Arcellx
Clin­i­cal stage de­vel­op­ment of Anti­gen Re­cep­tor Com­plex T-cells (ARC-T) that are read­i­ly si­lenced, ac­ti­vat­ed and re­pro­grammed in vi­vo by ad­min­is­tra­tion of a tu­mor-tar­get­ing anti­gen pro­tein called a sparX. Backed by NEA, No­vo, SR One, Take­da, So­las­ta, Quan, Clough, Mi­rae, JVC and LG. [more in­for­ma­tion]
AsclepiX Therapeutics
Lead com­pound AX­T107: nov­el pep­tide, in­hibit­ing VEGF and ac­ti­vat­ing Tie2 is the on­ly ther­a­peu­tic in clin­i­cal de­vel­op­ment for DME and wet AMD that was iden­ti­fied through a pro­cess of Ar­ti­fi­cial In­tel­li­gence, min­ing the hu­man pro­teome for cryp­tic an­ti an­gio­genic and home­o­stat­ic pep­tides, rather than through a stan­dard drug de­vel­op­ment pro­cess. [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung in­jury, Ph 3 trial is on­go­ing. [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] $147 MM MCap
Tar­get­ing HBV w/ oral core in­hibi­tors - po­ten­tial to in­crease cure rates. Lead can­di­date 731 in Ph 2: +ive safe­ty and de­creas­es in cc­cD­NA pop with pts ex­pect­ed to be with­drawn from treat­ment in 2020 and fol­lowed for sus­tained vi­ral DNA sup­pres­sion off ther­a­py. [more in­for­ma­tion]
Bellus Health [BLU] $477 MM MCap
BEL­LUS Health is de­vel­op­ing nov­el ther­a­peu­tics for the treat­ment of chron­ic cough and other hy­persen­si­ti­za­tion-re­lat­ed di­s­or­ders. BEL­LUS' lead prod­uct can­di­date, BLU-5937, is be­ing de­vel­oped for the treat­ment of chron­ic cough (Phase IIb SOOTHE pre-planned in­ter­im in Sept. 2021; to­p­line read­out in 4Q21) and chron­ic pru­ri­tus (Phase II BLUEPRINT read­out 4Q21). [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] $8,738 MM MCap
NURTEC® ODT ap­proved in 1Q20. NURTEC® ODT for pre­ven­ta­tive treat­ment of mi­graine ap­proved 1Q2021. 4Q21 exp. Ph3 MSA read­out. [more in­for­ma­tion]
BrainStorm Cell Therapeutics Inc. [BCLI] $112 MM MCap
NurOwn® au­tol­o­gous cell ther­a­py plat­form for neu­rode­gen­er­a­tive dis­eas­es. Lead can­di­date for ALS, Ph2 eval­u­at­ed 60 ALS pts w fa­vor­able safe­ty/tol­er­a­bil­i­ty. Ph3 cur­rent­ly en­rolling 200 pts across 6 US cen­ters; top-line da­ta ex­pect­ed in mid-2020. Phase 2 trial in pro­gres­sive MS on­go­ing at Cleve­land Clin­ic and Stan­ford Uni­ver­si­ty - to­p­line da­ta mid-2020. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] $161 MM MCap
Co-com­mer­cial as­set CNCT-19/CD19 CAR-T (part­nered w/ Ju­ven­tas): on­go­ing Ph 1 trials in B-NHL and B-ALL, exp to ini­ti­ate reg­is­tra­tion trials by YE 2020. Exp to ini­ti­ate Ph 1 study for CID-103 (an­ti-CD38 mAb) in EU in Q1 2021. [more in­for­ma­tion]
Cellular Biomedicine Group, Inc. [CBMG] $385 MM MCap
Vali­dates CB­MG's in-house cell man­u­fac­tur­ing ca­pa­bil­i­ties de­vel­oped in part­n­er­ship with Gen­er­al Elec­tric and Ther­mo Fish­er. CB­MG's pro­pri­e­tary im­muno-on­col­o­gy pipe­line in­cludes BC­MA, CD22, TCR-T for HCC and TIL for the treat­ment of NS­CLC and other solid tu­mors. [more in­for­ma­tion]
Genfit SA [GNFT] $168 MM MCap
De­vel­op­ment of po­ten­tial liv­er dis­ease treat­ment: ela­fi­branor in PBC: on­go­ing en­roll­ment for Ph 3 clin­i­cal trial EL­A­TIVE, fol­low-on PSC in­di­ca­tion. Com­mer­cial­iza­tion of NIS4™ for NASH di­ag­no­sis [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] $5,584 MM MCap
Chi-Med has a port­fo­lio of 8 drugs in clin­i­cal de­vel­op­ment from own dis­cov­ery en­gine in its In­no­va­tion plat­form and a cash gen­er­at­ing Com­mer­cial plat­form with 2,500+ sales reps. Glob­al col­lab­o­ra­tion with As­traZene­ca in two reg­is­tra­tion en­abling studies with savol­i­tinib in Ta­gris­so re­frac­to­ry lung can­cer that is MET+ and EGFRm+ (glob­al) and MET Ex­on 14 dele­tion NS­CLC (Chi­na). [more in­for­ma­tion]
Immatics NV [IMTX] $871 MM MCap
Im­mat­ics com­bines the dis­cov­ery of true tar­gets for can­cer im­munother­a­pies with the de­vel­op­ment of the right T cell re­cep­tors with the goal of en­abling a ro­bust and spe­cif­ic T cell re­sponse against th­ese tar­gets. We are com­mitt­ed to de­liv­er­ing the pow­er of T cells and to un­lock­ing new av­enues for pa­tients in their fight against can­cer. [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] $1,539 MM MCap
Aug 30 PD­U­FA da­ta for belu­mo­sudil (cGVHD) fol­low­ing pos­i­tive pri­mary anal­y­sis re­sults (May 2020); ob­served ORRs of 73% and 74% in 200mg QD and 200mg BID arms, re­spec­tive­ly. Ini­ti­at­ing 12-15 pt open-la­bel Ph 2 in pa­tients w dif­fuse cu­ta­neous sys­temic scle­ro­sis in Q1 2021. First 3-pt dose co­hort suc­cess­ful­ly com­plet­ed in on­go­ing dose-es­ca­la­tion Ph 1 (an­ti-PD-L1/IL-15 fu­sion pro­tein) in pa­tients w me­tastat­ic or lo­cal­ly ad­vanced solid tu­mors; en­roll­ment on­go­ing in next dose lev­el. Cont­inu­ing IND-en­abling ac­tivi [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $360M+ deal with Ge­nen­tech for KCP506, Ph1 non-opi­oid for chron­ic pain. [more in­for­ma­tion]
Lineage Cell Therapeutics Inc. [LCTX] $352 MM MCap
Cell ther­a­py com­pany with 3 clin­i­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]
Nanobiotix SA [NBTX] $446 MM MCap
Nano­bi­otix is a lead­ing, clin­i­cal-stage nanomedicine com­pany pi­oneer­ing new ap­proach­es to sig­ni­f­i­cant­ly change pa­tient out­comes by bring­ing nano­physics to the heart of the cell. Nano­bi­otix’s Im­muno-On­col­o­gy pro­gram has the po­ten­tial to bring a new di­men­sion to can­cer im­munother­a­pies. [more in­for­ma­tion]
Neoleukin Therapeutics [NLTX] $306 MM MCap
Lead prod­uct can­di­date, NL-201, is a de no­vo pro­tein de­signed to mim­ic the ther­a­peu­tic ac­tiv­i­ty of IL-2 and IL-15 for the treat­ment of can­cer. NL-201 is de­signed to elim­i­nate bind­ing to the al­pha sub­u­nit of the IL-2/CD25 re­cep­tor while main­tain­ing high-affini­ty bind­ing to the be­ta and gam­ma sub­u­nits. [more in­for­ma­tion]
NRx Pharmaceuticals, Inc. [NRXP] $552 MM MCap
Lead­ing Re­lief Ther­a­peu­tics Ph 2 trial of Avip­tadil to treat COVID-19 in­duced ARDS in the US. In Phase 3 with read­out ex­pect­ed mid-Jan­uary 2021. Al­so de­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. NRX-101 is in Ph 2b/3 de­vel­op­ment, (Break­through Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for Se­vere Bipo­lar De­pres­sion in pts w Acute Sui­ci­dal Idea­tion and Be­havior. [more in­for­ma­tion]
PAION AG [PA8:DE]
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2020. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €523 MM MCap
re­cent in-li­cense from No­var­tis of late stage drug Le­ni­olis­ib for APDS (ul­tra-rare im­mun­od­e­fi­cien­cy con­di­tion), rhC1INH for new larg­er in­di­ca­tions in­clud­ing COVID-19, pre-eclamp­sia, AKI and ad­di­tio­n­al pipe­line prod­uct from tech­nol­o­gy plat­form: re­com­bi­nant al­pha-Glu­cosi­dase for Pompe dis­ease. [more in­for­ma­tion]
Pharvaris [PHVS] $523 MM MCap
De­vel­op­ing PHA121, a high­ly po­tent, spe­cif­ic, and oral­ly bioa­vai­l­able com­pet­i­tive an­ta­g­on­ist of the bradykinin B2 re­cep­tor, cur­rent­ly in Ph 1 trial for the treat­ment of HAE. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] $301 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Pliant Therapeutics, Inc. [PLRX] $647 MM MCap
Fo­cused on dis­cov­er­ing and de­vel­op­ing ther­a­pies for the treat­ment of fi­bro­sis. Pliant's lead prod­uct can­di­date, PLN-74809, is an oral small-molecule du­al se­lec­tive in­hibi­tor of avß6 and avß1 in­te­grins that is in de­vel­op­ment for the treat­ment of idio­path­ic pul­mo­nary fi­bro­sis, and pri­mary scle­ros­ing cholan­gi­tis. Se­cond prod­uct can­di­date, PLN-1474, is a small-molecule se­lec­tive in­hibi­tor of avß1 for the treat­ment of liv­er fi­bro­sis as­so­ci­at­ed with NASH, which Pliant has part­nered with No­var­tis. [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] $1,473 MM MCap
Pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op oral tar­get­ed ther­a­py-based drugs and in­jecta­bles for rare dis­eas­es. PTG-300 in­jectable hep­cidin mimet­ic Ph 2 trials on­go­ing in po­ly­cythemia ve­ra and hered­i­tary he­mochro­ma­to­sis; pos­i­tive up­dat­ed Ph 2 re­sults in PV pre­sent­ed at ASH 2020. PN-943 oral GI-re­strict­ed al­pha-4-be­ta-7 an­ta­g­on­ist Ph 2 in ul­cer­a­tive coli­tis study sites ac­ti­vat­ed; PTG-200, part­nered w/ Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist Ph 2 Crohn’s dis­ease study on­go­ing. [more in­for­ma­tion]
Quentis Therapeutics
Lead pro­gram is a first-in-class IRE1&al­pha; in­hibi­tor de­signed to boost an­ti-tu­mor im­mu­ni­ty in can­cer. Quen­tis is pur­su­ing ther­a­pies to ad­dress mul­ti­ple ER stress path­way tar­gets in the tu­mor mi­cro-en­vi­ron­ment, as well as in other dis­eas­es where ER stress plays an im­por­tant role. Quen­tis launched in Fe­bruary 2018 with a $48 mil­lion Se­ries A fi­nanc­ing. [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] $136 MM MCap
Rare dis­eas­es; Keveyis for PPP revs ~21.7M for 2019 and $26 - $27M for 2020. Re­cor­lev for en­doge­nous Cush­ing's syn­drome Ph 3 pub­lished with to­p­line place­bo-con­trolled Ph 3 3Q20. [more in­for­ma­tion]
Targovax [TRVX]
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] $122 MM MCap
June 2019 pos­i­tive da­ta for TT­P399 as an add-on ther­a­py to in­sulin ther­a­py in a 12 week phase 1/2 trial in pa­tients with T1D. Re­sults from the se­cond part of the Ph2 study ex­pect­ed Q1 2020.&nb­sp;Re­cent­ly an­nounced the first pa­tient has been screened for the Ph2 proof of con­cept study eval­u­at­ing the safe­ty and ef­fi­ca­cy of azeli­ra­gon in pa­tients with mild Alzheimer's dis­ease and Type 2 Di­a­betes. [more in­for­ma­tion]
Yisheng Biopharma
De­vl bio­ther­a­peu­tics for can­cers and in­fec­tious dis­ease. Prod­ucts in de­vt in­clude Ph 1 IO prod­uct tar­get­ing solid tu­mors Ph 3 PI­KA vaccine tar­get­ing hep B and ra­bies in­fec­tions. [more in­for­ma­tion]